SCHEMBL6255264

SCHEMBL6255264

Cn1c(-c2ccccc2)nc(-c2ccccc2)c1C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 1/20 0.51
DHODH Q02127 2/20 0.49
CYP1A2 P05177 2/20 0.45
TSHR P16473 1/20 0.44
PDE10A Q9Y233 1/20 0.44
ADORA2A P29274 1/20 0.43
ADORA2B P29275 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
PIN1 Q13526 1/20 0.42
GRIA2 P42262 1/20 0.42
GRIA4 P48058 1/20 0.42
KDM4E B2RXH2 2/20 0.42
LMNA P02545 1/20 0.42
CGAS Q8N884 1/20 0.42
NR1H2 P55055 1/20 0.41
NR1H3 Q13133 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6255283 0.87 PTGER1 (0.46) PTGER1DHODHCYP1A2ADORA2AADORA2B
SCHEMBL6259295 0.87 MEN1 (0.54) DHODHMEN1KMT2AKDM4ELMNA
SCHEMBL8823133 0.84 HSD11B1 (0.52) PTGER1DHODHKMT2AGRIA2GRIA4
SCHEMBL6260789 0.84 NPC1 (0.46) DHODHADORA2AKMT2ASMN1; SMN2KDM4E
SCHEMBL6257997 0.82 CYP1A2 (0.62) CYP1A2MEN1KMT2ASMN1; SMN2CYP2C9
SCHEMBL6261495 0.79 MEN1 (0.46) CYP1A2ADORA2AADORA2BMEN1KMT2A
SCHEMBL14953565 0.79 KDM4E (0.40) PTGER1DHODHCYP1A2TSHRPDE10A
SCHEMBL14953694 0.79 CNR1 (0.41) DHODHCYP1A2TSHRPDE10AMEN1
SCHEMBL19864297 0.78 ALDH1A1 (0.55) CYP1A2TSHRMEN1KMT2ASMN1; SMN2
SCHEMBL11312831 0.77 CYP1A2 (0.58) PTGER1DHODHCYP1A2ADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005066137-A1 2,5-DIARYL-1H-IMIDAZOLE-4-CARBOXAMIDES AS NEUROKININ-3 RECEPTOR MODULATORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM AND PERIPHERAL DISEASES NEUROGEN CORPORATION (US) 2005-07-21 WO disclosed
US-20050148601-A1 Neurokinin-3 receptor modulators: diaryl imidazole derivatives NEUROGEN CORPORATION 2005-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148601-A1 Neurokinin-3 receptor modulators: diaryl imidazole derivatives TACR1, TACR2, TACR3 PTGER1 412/4885DHODH 3095/4885CYP1A2 1918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.